Teriparatide is a synthetic form of parathyroid hormone (PTH) [1]. It is classified as an anabolic agent used in the treatment of osteoporosis [2].
What is Teriparatide used to treat?
Teriparatide is prescribed for individuals with a high risk of fracture who have osteoporosis [2]. This includes postmenopausal women and men with osteoporosis, as well as those with osteoporosis associated with sustained high-dose glucocorticoid therapy [3]. It is designed to stimulate bone formation [2].
How does Teriparatide work?
Teriparatide mimics the action of endogenous parathyroid hormone [4]. By administering it intermittently, it stimulates osteoblasts, the cells responsible for building new bone tissue [4]. This anabolic effect leads to an increase in bone mineral density and a reduction in the risk of fractures [4].
When does Teriparatide's patent exclusivity expire?
Patent exclusivity for drugs like teriparatide can be complex and vary by specific patent and region. Information on the patent status and expiry dates for teriparatide and related formulations can be found on resources such as DrugPatentWatch.com [5].
What are the potential side effects of Teriparatide?
Common side effects reported with teriparatide use include nausea, joint pain, leg cramps, and pain [3]. In some cases, dizziness or increased heart rate may occur [3]. Patients should discuss any potential side effects with their healthcare provider [3].
Are there alternative treatments for osteoporosis?
Yes, alternative treatments for osteoporosis exist. These may include other anabolic agents, antiresorptive medications such as bisphosphonates and denosumab, and lifestyle modifications [6]. The choice of treatment depends on individual patient factors, risk assessment, and medical history [6].
What is the difference between Teriparatide and other osteoporosis drugs?
Teriparatide is an anabolic agent, meaning it builds new bone, whereas many other osteoporosis medications are antiresorptive, meaning they slow down bone loss [4]. This difference in mechanism of action can influence their effectiveness and patient suitability [4].
Who manufactures Teriparatide?
Teriparatide has been marketed under brand names such as Forteo by Eli Lilly and Company. Generic versions are also available from various pharmaceutical manufacturers [7].
What clinical data supports Teriparatide's use?
Clinical trials have demonstrated that teriparatide significantly reduces the risk of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis [4]. Studies also show increases in bone mineral density in men and women treated with the drug [4].
What are the risks associated with Teriparatide?
A boxed warning for teriparatide advises of a potential increased risk of osteosarcoma, a type of bone cancer, observed in animal studies [3]. While the relevance to humans is uncertain, this risk needs to be considered when determining patient eligibility [3]. Teriparatide is not recommended for patients with certain pre-existing conditions, such as Paget's disease of bone or unexplained elevations of alkaline phosphatase [3].
How is Teriparatide administered?
Teriparatide is administered as a daily subcutaneous injection [1]. The typical duration of treatment is 24 months [1].
Sources:
[1] https://www.drugpatentwatch.com/drugs/teriparatide
[2] https://www.drugpatentwatch.com/drug-classes/anabolic-agents
[3] https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/021317s038,021744s011lbl.pdf
[4] https://www.ncbi.nlm.nih.gov/books/NBK279049/
[5] https://www.drugpatentwatch.com/
[6] https://www.niams.nih.gov/health-topics/osteoporosis
[7] https://www.drugpatentwatch.com/search/teriparatide